An Educational Intervention to Improve HPV Vaccination: A Cluster Randomized Trial by Dixon, Brian E. et al.
An Educational Intervention to Improve HPV Vaccination: 
A Cluster Randomized Trial 
Brian E. Dixon, MPA, PhD1,2,3*, Gregory D. Zimet, PhD4, Shan Xiao, PhD1, Wanzhu Tu, PhD1, 
Brianna Lindsay, PhD5, Abby Church, MPH2, Stephen M. Downs, MD, MS2,4 
Affiliations: 1Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, 
IN; 2Regenstrief Institute, Inc., Center for Biomedical Informatics, Indianapolis, IN; 3Center for 
Health Information and Communication, Department of Veterans Affairs, Veterans Health 
Administration, Health Services Research and Development Service, Indianapolis, IN; 4Indiana 
University School of Medicine, Department of Pediatrics, Indianapolis, IN; Merck & Co., Inc., 
Kenilworth, NJ, USA 
Address correspondence to: Brian E. Dixon, Department of Epidemiology, Indiana University 
Richard M. Fairbanks School of Public Health, 1050 Wishard Blvd, RG5, Indianapolis, IN 
46202, bedixon@regenstrief.org, 317-278-3072 
Short Title: A Video Intervention for HPV Vaccination 
Financial Disclosure: The Child Health Improvement through Computer Automation (CHICA) 
system is the intellectual property of Indiana University. Stephen Downs is a cofounder of 
Digital Health Solutions, LLC, a company created to license and market CHICA. This company 
was founded after the completion of the study. The other authors have no financial relationships 
relevant to this article to disclose. 
Funding source: This study was supported by the Merck-Regenstrief Program in Personalized 
Health Care Research and Innovation (Project #20). Its contents are the sole responsibility of the 
authors and do not reflect the official view of Merck & Co., Inc., Kenilworth, NJ, USA. 
Potential Conflicts of Interest: Gregory Zimet has been an investigator on investigator-initiated 
research funded by Merck & Co., Inc., Kenilworth, NJ, USA and Roche, received travel funding 
from Merck & Co., Inc., Kenilworth, NJ, USA to present research at a scientific conference, and 
received an honorarium for participation in an adolescent immunization initiative meeting. 
Brianna Lindsey is an employee of Merck & Co., Inc., Kenilworth, NJ, USA. Stephen Downs is 
a cofounder of Digital Health Solutions, LLC, Indianapolis, IN, USA, a company created to 
license and market the Child Health Improvement through Computer Automation (CHICA) 
system. Brian Dixon, Shan Xiao, Wanzhu Tu, and Abby Church have no potential conflicts of 
interest to report. 
ClinicalTrials.gov # NCT02546752 “Use of a Patient Education/Messaging Platform to Increase 
Uptake and Series Completion of the HPV Vaccine” 
Abbreviations: HPV, Human Papillomavirus; CHICA, Child Health Improvement through 
Computer Automation system; EHR, electronic health record 
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Dixon, B. E., Zimet, G. D., Xiao, S., Tu, W., Lindsay, B., Church, A., & Downs, S. M. (2019). An Educational Intervention to 
Improve HPV Vaccination: A Cluster Randomized Trial. Pediatrics, 143(1), e20181457. https://doi.org/10.1542/peds.2018-1457
Table of Contents Summary 
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Human Papillomavirus (HPV) remains the most common sexually transmitted infection. Despite 
availability of effective vaccines, HPV vaccination rates are suboptimal. Prior research on 
improving HPV vaccination rates has focused primarily on decision aids that target providers. 
 
What This Study Adds 
Patient-centered education strategies delivered in a clinic setting via information technology 
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Background: Human Papillomavirus (HPV) infection can lead to serious health issues and 
remains the most common sexually transmitted infection. Despite availability of effective 
vaccines, HPV vaccination rates are suboptimal.  
Methods: In a cluster randomized trial, an intervention targeting parents of adolescents (11-17 
years) eligible for a dose of HPV vaccine was tested in pediatric clinics part of an urban health 
system. Parents watched a digital video outlining the risks and benefits of vaccine using a tablet 
in the exam room. The primary outcome was change in HPV vaccine status two weeks after the 
clinic visit. An intention to treat analysis for the primary outcome utilized generalized estimating 
equations to accommodate the potential cluster effect of clinics. 
Results: A total of 1596 eligible adolescents were observed during the 7-month trial. One-third 
of adolescents visited an intervention clinic. Adolescents who attended an intervention clinic 
were more likely to be younger (11-12 years) than those who attended a control clinic (72.4% 
versus 49.8%; p<0.001). No differences in race or gender were observed. The proportion of 
adolescents with an observed change in vaccine status was higher for those attending an 
intervention clinic (64.8%) versus control clinic (50.1%; OR=1.82; 95% CI=1.47-2.25; p<0.001). 
Adolescents whose parents watched the video had a three times greater odds of receiving a dose 
of the HPV vaccine (78.0%; OR=3.07; 95% CI=1.47-6.42; p=0.003).  
Conclusions: Educational interventions delivered within a clinical setting hold promise to 




Human papillomavirus (HPV) is the most common sexually transmitted infection in the U.S., with 
approximately 79 million infected and 14 million new cases each year.1 Infection with HPV is a 
causal factor for serious health issues including cervical, vaginal, and vulvar cancers in women, 
anal and oropharyngeal cancers as well as genital warts and recurrent respiratory papillomatosis 
in males and females, and penile cancer in men;2 making HPV a significant threat to public health. 
Moreover, many HPV infections are preventable via vaccination. The Advisory Committee on 
Immunization Practices (ACIP) recommends that HPV vaccine be routinely administered to early 
adolescents (i.e., 11–12-year-olds) in the United States.3 Healthy People 2020 goals for vaccine 
coverage include 80.0% of individuals completing the HPV vaccine series by age 13-15.4 Despite 
availability of the 9-valent HPV vaccine (9vHPV) that can prevent up to 90.0% of cervical cancers 
and genital warts,5 HPV vaccination rates in the U.S. remain well below the Healthy People 2020 
goals.6 In 2016, only 65.1% of adolescent girls and 56.0% of adolescent boys ages 13 through 17 
years received one or more doses of vaccine.7 The percentages are even lower for series completion 
(49.5% of girls and 37.5% of boys). With respect to Indiana, 2016 data show the state to be ranked 
46th in first dose administration among females and tied for last for males.7 
Prior research on interventions to improve HPV vaccination rates focused on three levels: 
community, provider, and consumer (parent/adolescent). At the community level, there is 
moderate-level evidence across studies in multiple countries for policies that can nearly double 
HPV vaccination rates among adolescents, such as requiring vaccination for school-age children.8 
While effective, public health strategies are often challenging to implement. 
Evidence at the provider level is mixed. A small set of clinical decision support (CDS) 
interventions to increase provider recommendation of the vaccine to parents or adolescent patients 
have been developed and tested, because provider recommendation is consistently cited as a 
primary reason that parents vaccinate or indicate intent to vaccinate their adolescent children.9-11 
Of the prior studies (N=6) examining CDS interventions, half found no difference in HPV 
vaccination rates post-intervention.12-16 While these studies suggest CDS prompts are associated 
with provider recommendation of the HPV vaccine, the evidence also suggests achieving the 
Healthy People 2020 goal will require more than just provider-based CDS prompts. 
Evidence for interventions at the consumer level is positive but weak. A heterogeneous set of 
studies (N=12)8,12 examined interventions that target parents and adolescents. These interventions 
typically involved postal or telephone-based reminders that the adolescent was due to start or 
complete the HPV series. Two of the studies examined video-based interventions targeting high 
school and college age female students.17,18 Two review articles8,12 concluded that most of these 
interventions improved HPV vaccination uptake. Yet the methods employed in these studies were 
generally weak with many lacking a control group. Furthermore, few studies targeted younger 
adolescents, and few took place within a typical outpatient clinic setting.  
While prior research provides a foundation that suggests a combination of community, provider 
and consumer directed interventions will be required to achieve the Healthy People 2020 goals, 
there is limited evidence on the best strategies to reach younger adolescents of both genders in 
typical pediatric clinic settings. In particular, there is a dearth of evidence on whether and how 
digital technologies can support informed decision-making about preventative health behaviors. 
Objectives of the study 
Given poor HPV vaccination rates in Indiana as well as limited evidence on consumer-centered 
technology applications that can be deployed in a typical clinical setting, we designed a cluster 
randomized trial to test the effect of a digital HPV vaccine educational intervention to be delivered 
during a clinic visit. Our study contributes evidence on whether and how information technologies 
can increase awareness and support parental decision-making about prevention behaviors such as 
vaccination. In this paper, we summarize the results of the trial. 
Patients and Methods 
Study design 
The study employed a cluster randomized trial with 2-arm design to examine the efficacy of an 
education intervention on HPV vaccine series 1st dose (initiation), 2nd dose, and/or 3rd dose 
(completion) among 11-17 year old boys and girls from October 2015 to May 2016. Five urban 
health clinics were grouped into clusters based on patient volume, race, and gender. Clusters were 
randomized by coin flip. After randomization, the intervention cluster contained two clinics and 
the control cluster contained three clinics. The study was approved by the Indiana University 
Institutional Review Board. The IRB waived the requirement for written informed consent. 
Setting 
Eskenazi Health is one of the five largest safety net health systems in the United States. The health 
system contains a 315-bed hospital and nine community health centers located across the 
metropolitan area of Indianapolis, Indiana; the eleventh largest city in the United States. All five 
pediatric clinics within the health system served as the setting for this study. 
Technical system 
The Child Health Improvement through Computer Automation system (CHICA) is an operational 
CDS system used in the five pediatric clinics for over 12 years.19 When a child signed into one of 
the pediatric clinics, the EHR system sent an HL7 ADT (registration) message to CHICA. In 
response, CHICA queried the patient’s medical record. At the same time, the system sent an HL7 
request to CHIRP (Children and Hoosier Immunization Registry Program), Indiana’s 
immunization information system (IIS).20,21 In response, CHICA received a download of the 
child’s immunization history. The download included CHIRP’s “forecast” of the immunizations 
for which the patient was due. The electronic transfer of immunization information between 
CHICA and CHIRP is a form of health information exchange (HIE).22 
Theo™ is an interactive, consumer-directed mHealth software developed by Noble.MD (recently 
acquired by WellTrackOne; Hilton Head Island, SC) that functions on a tablet platform. Theo™ 
can screen for health risks at the point-of-care using validated screening surveys, identify specific 
patient risks, and deliver a standardized educational video in real time. Theo™ measures pre- and 
post-intervention patient knowledge, attitudes, readiness for change, and risk mitigation. Theo™ 
can create a HIPAA-compliant digital record that can be integrated into an EHR. 
The technical system integrating CHICA and Theo™ is summarized in Figure 1. Once CHICA 
determined an adolescent registered into the clinic to be eligible for the intervention by analyzing 
their combined medical record (1) and immunization registry (2) data, a medical assistant (MA) in 
the clinic was notified (3) and provided the patient’s study identifier (a randomly generated study 
ID). The MA then provided the parent of the adolescent with a tablet and entered the study 
identifier into the THEOTM software (4). One of two programs then launched (5), depending on 
the adolescent’s current HPV vaccination status. 
The first program, created for adolescents who had not yet received the first dose of the HPV 
vaccine, assessed whether the family had already decided in favor of the HPV vaccine or if the 
family wanted more information. If the system determined the family was in favor of receiving a 
vaccine at the visit, the program provided a simple reinforcement message. If the family indicated 
a desire for more information about the HPV vaccine, the program provided information specific 
to the cancer prevention benefits and safety profile of the vaccine. The second program, for 
adolescents who had already received the first or second vaccine in the series, emphasized the need 
to make the first vaccine count by receiving the full series. Both programs were available in 
English and Spanish. 
<Insert Figure 1 approximately here> 
The program scripts were created by several authors (GZ, SD, BED, BL) with expertise in 
adolescent health, HPV vaccination, epidemiology and health communication. Although not 
assessed in this paper, the scripts and questions used by participants was guided by the Theory of 
Planned Behavior, which has been used in prior HPV vaccine uptake research.23,24 Once finalized, 
the scripts were recorded in English and Spanish then integrated into the THEOTM platform. The 
scripts are available for review and use by others following permission from the authors. 
Participants 
Participants were parents or guardians of unvaccinated and partially vaccinated adolescents aged 
11-17 as of the date of visit during the study period. All parents or guardians of adolescents 
attending intervention clinics were potentially eligible. Parents were excluded if their children had 
received the full HPV vaccination series. Parents further needed to read and comprehend either 
English or Spanish. 
Data management and analysis 
Spurious records were removed prior to analysis (25 out of 1621 were deleted). These records were 
either missing key values, such as a determination of whether or not the adolescent received a dose 
of the HPV vaccine, or calculated values were out of range (e.g., adolescent went from having the 
first dose of HPV vaccine prior to the visit to having not started the vaccine series two weeks after 
the encounter). 
Demographic and insurance data were summarized by treatment group to examine the overall 
characteristics of the cohort. Continuous variables were summarized using means and standard 
deviations. Comparisons were made between the two treatment groups using t tests. Categorical 
variables were summarized using proportions and differences between proportions and 
significance testing was carried out with the Chi-square test. 
The primary outcome of interest was HPV vaccine uptake, defined as a change in vaccination 
status as a result of a clinic visit. Vaccination status could be one of four potential states: 1) ‘patient 
lacks documentation on starting the series’; 2) ‘patient had documented first dose’; 3) ‘patient had 
documented second dose’; or 4) ‘patient had documented third or final dose’. Documentation was 
determined by CHICA which integrated records from both the adolescent’s EHR and CHIRP, the 
state immunization registry. The outcome variable was modeled as a binary change between two 
time periods where a value of ‘1’ represented a change in status (or state). A two-week window 
was observed following a clinic visit to allow for any vaccines delivered in the clinic during an 
encounter to be recorded in the EHR or CHIRP. 
To analyze the effect of the intervention on vaccine uptake, we employed an intention to treat 
(ITT) analysis using generalized estimating equations (GEE) to accommodate the potential cluster 
effect of clinics, when a significant cluster effect was identified. Specifically, GEE accounts for 
the correlations in treatment outcomes from children seen at the same clinic. GEE is frequently 
used in generalized linear models for correlated data and produces robust standard error 
estimates.25 We performed two ITT analyses to compare vaccine uptake in 1) the intervention 
versus control clinics as well as 2) the group of adolescents who received the tablet versus those 
who did not receive the intervention. All significance testing was two-tailed and the significance 




A total of 1,596 adolescents visited one of the clinics during the seven month trial. One-third 
(N=537) visited an intervention clinic with the remainder visiting a control clinic. The 
characteristics of the cohort are summarized in Table 1. Overall, adolescents were predominantly 
non-white, 11-12 years of age, and had Medicaid insurance.  
Gender and race were similar between intervention and control clinics. Adolescents attending the 
two intervention clinics were slightly younger, on average, than those who attended the control 
clinics (mean age 12.2 years versus 12.9 years, p < 0.001). The study arms also differed by 
insurance type with adolescents attending the intervention clinics more likely to have commercial 
or Medicaid insurance and less likely to be self-pay or other form of insurance than those attending 
the control clinics (p < 0.001). 
<Insert Table 1 Approximately Here> 
Intervention effect 
Vaccine status during visits as well as two weeks following visits is summarized in Figure 2. 
Similar patterns are observed across intervention and control clinics. The proportion of adolescents 
with no dose of the HPV vaccine two weeks after a clinic visit (36.2%) is lower than at the time 
of the visit (56.8%). In parallel there is a rise in the proportion of adolescents with a documented 
first, second, or third dose of the vaccine two weeks after a clinic visit. The exception to this pattern 
is in the intervention clinics, where the proportion of adolescents with a documented first dose 
actually fell slightly two weeks post-visit (29.1% to 27.9%). 
<Insert Figure 2 approximately here> 
Results of the ITT analysis examining the effect of the intervention are summarized in Table 2. 
Of those presenting to a control clinic, 531 (50.1%) received a dose of the HPV vaccine within 
two weeks of a visit. Of those presenting to an intervention clinic, 348 (64.8%) received a dose of 
the HPV vaccine within two weeks of the visit. Comparing HPV vaccination uptake (e.g., a change 
in HPV dose status) between intervention and control clinics, adolescents presenting to an 
intervention clinic had nearly double the odds of receiving a dose of the HPV vaccine (OR, 1.82, 
95% CI, 1.47-2.25, p<0.001).  
A total of 141 (25% of those presenting to an intervention clinic) adolescents received a tablet 
from a medical assistant during their visit. Nearly four-fifths (78.0%) of these adolescents received 
a dose of the HPV vaccine. Slightly more than half (52.8%) of adolescents who did not receive a 
tablet received a dose of the vaccine. Comparing HPV vaccination uptake between these groups, 
adolescents who received a tablet had three times greater odds of receiving a dose of the HPV 
vaccine (OR, 3.07, 95% CI, 1.47-6.42, p=0.003).  For this analysis, the cluster effect was 
significant (p=0.005), therefore the GEE accounted for the clustering by clinic. 
<Insert Table 2 Approximately Here> 
Discussion 
In a cluster randomized trial across five pediatric clinics within an urban health system, we 
examined the effect of a digital educational intervention aimed at increasing HPV vaccination 
uptake among adolescents. At intervention sites, a video on the risks and benefits of the HPV 
vaccine or reinforcement message was presented on a mobile tablet to parents or guardians of 
eligible adolescents in an exam room while they waited for clinicians during a routine, non-acute 
care visit.  
The efficacy of the tablet-based educational intervention was significant, tripling the odds of HPV 
vaccine uptake among adolescents who received the tablets. Viewing tailored messages on the 
tablets with respect to vaccine initiation or series completion likely ‘activated’ families to either 
request the vaccine or discuss the vaccine with providers during the visit. It is further likely that, 
when families asked about the vaccine following use of the tablets, providers delivered positive 
reinforcement messages that also contributed to vaccine uptake, a ‘feature’ of interventions like 
the one used in this study. These results suggest that patient-centered education strategies delivered 
in a clinic setting via information technology platforms can positively impact the adoption of 
preventive health behaviors. 
This study adds to our understanding of consumer-oriented interventions that seek to improve HPV 
prevention behaviors. Prior studies8,12 employed a heterogeneous set of communication media to 
reach adolescents or their parents, with most studies employing automated phone call reminders. 
Just two studies17,18 utilized interactive computer-based approaches. In DiClemente et al.,18 
adolescent females 14-18 years in age viewed a 12-minute interactive media presentation. 
Researchers observed a significant difference only in completion of the second dose of the HPV 
vaccine; there was no change in initiation rate and there was a non-significant increase in 
completion of the third dose. In Hopfer et al.,17 female college students 18-26 years in age watched 
videos of vaccine decision narratives delivered by peers, medical experts, or a combination of 
peers and experts. Women who watched the videos delivered by a combination of peers and experts 
were almost twice as likely as controls to vaccinate within two months of watching the video.17 
Compared with prior studies, our study included younger adolescents (11-17 years of age) and 
observed significant increases in series initiation as well as second and third doses of the vaccine. 
The younger population in the intervention clinics may explain, in part, impact on series initiation 
as compared to DiClemente et al.18 
The impact of consumer-oriented educational interventions on public health could be significant 
if broadly used across the health system. Vaccination rates against HPV remain low in Indiana and 
many other states for early adolescents.7 Vaccine series completion rates also remain well below 
the Healthy People 2020 goals, especially for adolescent males. An educational intervention 
accessible to adolescents as well as their parents or guardians could support more informed 
decision-making about the risks of HPV infection and benefits of vaccination. Moreover, an 
educational intervention might enable additive effects when combined with community- and 
provider-oriented interventions, which prior research suggests can also improve vaccination 
rates.8-11  
A key component of the intervention was the interoperable HIE network that enabled the CHICA 
system to gather and integrate data from the health system’s commercial EHR as well as the state 
IIS, known as CHIRP in Indiana. Automated query and integration of vaccine history information 
to the point of care provided a strong infrastructure26,27 upon which the intervention could be tested. 
While HIE networks exist elsewhere, the technical architecture and approach used in this study 
would likely need to be adapted to succeed in states with less comprehensive HIE networks or IIS.   
While the results from this trial are encouraging, implementing the trial involved several 
challenges. A major challenge was distribution of the tablets to eligible patients. Only a quarter of 
eligible patients received a tablet upon clinic check-in. This presented a logistical barrier. Before 
providing a tablet to a patient, the MA had to be alerted by CHICA to the patient’s eligibility and 
manually enter the patient’s trial study identifier into the tablet. These steps proved quite 
challenging for a busy pediatric clinic environment. If tablets were routinely distributed to all 
patients of a certain age, or every patient regardless of age, and patients could use the tablets to 
view a variety of content, then administration of the devices might be easier on clinic staff.  
Another challenge was variable wait times, since some providers came into the room just before 
or during the video interaction. Similarly, some clinics take patients right away to the exam room, 
while other clinics routinely have waiting periods in a lobby. These present challenges as to when 
it would be an appropriate time to ask patients to interact with a tablet to view an educational 
intervention. One possibility for future research would be to examine pre-visit delivery of videos 
and interactive media using the Internet or mobile phone to view an educational intervention 24-
48 hours prior to the visit. A recent review by Badawy and Kuhns,28 which examined mobile phone 
applications designed to support positive adolescent preventative health choices, concluded that 
less than half of the studies (N=19) observed a significant improvement in prevention decisions. 
Additional studies on mobile interventions would contribute to the growing evidence base on 
consumer-focused informatics applications.29  
Limitations 
This study has three limitations of note. First, the clustering of clinics occurred within a single, 
urban health system cautioning broad generalizations across all care settings. Additional testing 
across a variety of settings and multiple health systems would be necessary to demonstrate 
sustained effects prior to adoption into routine care. Second, the mere presence of the tablets in the 
clinic might have influenced provider behavior for all patients in that clinic (e.g., un-blinding) 
rather than just those patients who received the tablets. Finally, the outcome was modeled as a 
dichotomous variable with respect to a change in vaccine status. Because analysis was not 
performed separately for vaccine initiation versus series completion, the intervention may have 
had more effect on one of these groups of patients since the educational software showed different 
videos to each group of patients. Future research should explore whether educational interventions 
are more effective for initiation or completion.  
Conclusions 
In a cluster randomized trial of an educational intervention to improve HPV vaccination rates 
delivered via a digital tablet in an exam room, efficacy was high. While results are promising, the 
intervention occurred at two clinics in a single urban health system. An expanded, multisite trial 
of the intervention, perhaps in combination with an intervention targeting providers, would be 
necessary to demonstrate both how the intervention could scale across the health system and how 
the intervention might work in combination with other evidence-based methods for improving 
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Legends for Figures 
Figure 1 – Information architecture and workflow used to trigger a clinical encounter involving 
the tablet educational intervention. As patients sign into the clinic, vaccination records are gathered 
electronically from the EHR and IIS. The CHICA CDSS determines eligibility and notifies the 
MA if the patient should receive a tablet and provides a subject identifier. The subject ID is entered 
into the tablet, which is given to the parent of the adolescent as the MA escorts them back to the 
exam room. EHR = Electronic health record; IIS = Immunization information system; CDSS = 
Clinical decision support system; CHICA = Child Health Improvement through Computer 
Automation; MA = Medical assistant 
 
Figure 2 Proportion of control and intervention clinic populations with no dose, one dose, two 
doses, and three doses of the HPV vaccine at the time of clinic visit and again two weeks after visit 
during the six month trial of a tablet-based educational intervention. 
  
Table 1. Characteristics of Adolescents Visiting Control and Intervention Clinics in the Eskenazi 
Health System in Indianapolis, Indiana, Between October 12, 2015, and April 12, 2016 
Characteristic Overall, 
N = 1596 
Control, 
N = 1059 
Intervention, 
N = 537 
P 
Sex, n (%)       0.474 
 Female 723 
(45.3) 
473 (44.7) 250 (46.6)   
 Male 873 
(54.7) 
586 (55.3) 287 (53.4)   
Race, n (%)       0.128 
 White 141 (8.8) 100 (9.4) 41 (7.6)   
 African American 870 
(54.5) 
559 (52.8) 311 (57.9)   
 Other or unknown 585 
(36.7) 
400 (37.8) 185 (34.5)   
Insurance, n (%)       <.001 
 Medicaid 1241 
(77.8) 
796 (75.2) 445 (82.9)   
 Commercial 101 (6.3) 64 (6.0) 37 (6.9)   
 Self-pay 53 (3.3) 43 (4.1) 10 (1.9)   
 Other or unknown 201 
(12.6) 
156 (14.7) 45 (8.4)   
Age, y, n (%)       <.001 
 11–12 916 
(57.4) 
527 (49.8) 389 (72.4)   
 13–14 409 
(25.6) 
320 (30.2) 89 (16.6)   
 15–17 271 
(17.0) 
212 (20.0) 59 (11.0)   
Table 2. Association Between Digital Educational Intervention and HPV Vaccination Uptake in 














          
 Adolescents who 
presented to an 
intervention clinic 
537 348 (64.8) 1.82 1.47–
2.25 
<.001 
 Adolescents who 
presented to a control 
clinic 
1059 531 (50.1) N/A N/A Reference 
Tablet versus no tablet           
 Subjects who received a 
tablet during clinic visit at 
an intervention clinic 
141 110 (78.0) 3.07 1.47–
6.42 
0.003 
 Subjects who did not 
receive a tablet during 
clinic visit at a control or 
intervention clinic 
1455 768 (52.8) N/A N/A Reference 
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